Online citations, reference lists, and bibliographies.
← Back to Search

MA 19.01 A Phase II Study Of Nivolumab: A Multicenter, Open-Label, Single Arm Study In Malignant Pleural Mesothelioma (MERIT)

Y. Goto, M. Okada, T. Kijima, K. Aoe, T. Kato, N. Fujimoto, K. Nakagawa, Y. Takeda, T. Hida, K. Kanai, F. Imamura, S. Oizumi, T. Takahashi, M. Takenoyama, H. Tanaka, Y. Ohe
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background: Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy with poor prognosis and limited treatment options beyond progression after platinum-based combination with pemetrexed chemotherapy. Nivolumab (anti-PD-1, ONO-4538, BMS-936558), a humanized monoclonal antibody



This paper is referenced by
10.1007/s12032-018-1156-x
Is there a role for immunotherapy in malignant pleural mesothelioma?
A. Tartarone (2018)
10.1016/j.critrevonc.2019.102815
Emerging therapies in malignant pleural mesothelioma.
M. Cinausero (2019)
10.1016/j.pharmthera.2018.09.008
Targeting Programmed Cell Death ‐1 (PD‐1) and Ligand (PD‐L1): A new era in cancer active immunotherapy
A. Constantinidou (2019)
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1007/s11748-020-01329-y
Conversion surgery for locally advanced malignant pleural mesothelioma
Y. Terada (2020)
10.1016/j.jtho.2019.08.2506
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
10.1016/j.jtho.2018.08.2024
Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus.
C. J. de Gooijer (2018)
10.1016/j.cllc.2018.05.001
A Phase II Trial of First‐Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
N. Fujimoto (2018)
10.1080/17476348.2019.1563488
Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
L. Ye (2019)
10.1093/jjco/hyz104
Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
Y. Nagata (2019)
Semantic Scholar Logo Some data provided by SemanticScholar